Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. NewAmsterdam Pharma Company NV shares valued at $205,567 were sold by Kooij Louise Frederika on Aug 25 ’25. At $24.86 per share, Kooij Louise Frederika sold 8,269 shares. The insider’s holdings dropped to 15,000 shares worth approximately $0.36 million following the completion of this transaction.
Also, Kooij Louise Frederika purchased 8,269 shares, netting a total of over 208,296 in proceeds.
Before that, Kastelein Johannes Jacob Piete had sold 50,000 shares from its account. In a trade valued at $1,257,140, the Chief Scientific Officer traded NewAmsterdam Pharma Company NV shares for $25.14 each. Upon closing the transaction, the insider’s holdings decreased to 50,000 shares, worth approximately $1.66 million.
As published in their initiating research note from Wells Fargo on August 25, 2025, NewAmsterdam Pharma Company NV [NAMS] has been an Overweight and the price target has been revised to $45. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid July. As of June 17, 2025, Citigroup has initiated its “Buy” rating for NAMS. Earlier on June 10, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
On last trading session, NewAmsterdam Pharma Company NV [NASDAQ: NAMS] plunged -2.13% to $23.95. The stock’s lowest price that day was $23.81, but it reached a high of $24.805 in the same session. During the last five days, there has been a drop of approximately -2.00%. Over the course of the year, NewAmsterdam Pharma Company NV shares have jumped approximately 42.90%. Shares of the company reached a 52-week high of $26.80 on 01/02/25 and a 52-week low of $14.06 on 04/07/25.
Support And Resistance Levels for NewAmsterdam Pharma Company NV (NAMS)
According to the 24-hour chart, there is a support level at 23.57, which, if violated, would cause prices to drop to 23.19. In the upper region, resistance lies at 24.57. The next price resistance is at 25.18. RSI (Relative Strength Index) is 51.14 on the 14-day chart, showing neutral technical sentiment.
Is NewAmsterdam Pharma Company NV subject to short interest?
Stocks of NewAmsterdam Pharma Company NV saw a sharp rise in short interest on 2025-08-15 jumping by 0.45 million shares to 7.33 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 6.88 million shares. A jump of 6.14% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.09 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.09.
Which companies own the most shares of NewAmsterdam Pharma Company NV (NAMS)?
In terms of NewAmsterdam Pharma Company NV share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 75.73% from the previous closing price of $24.47. Analysts anticipate NewAmsterdam Pharma Company NV stock to reach 45 by 2025, with the lowest price target being 41. In spite of this, 1 analysts ranked NewAmsterdam Pharma Company NV stock as Buy at the end of 2025. On June 04, 2025, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $42.
